Risk Factors Update Summary
- Increased complexity in manufacturing may lead to delays or halts in production, impacting supply. This could result in significant delays in clinical trials or commercial sales.
- The number of employees increased from 164 to 185, indicating a 21-employee growth.
- The accumulated deficit increased from $426.5 million to $537.3 million, a $110.8 million rise.
- The company submitted a BLA for a specific indication, receiving priority review from the FDA.
- The company had cash and cash equivalents decrease from $151.9 million to $80.4 million.
- The company may issue additional shares, potentially diluting existing stockholders' ownership interest.
- The company's management team and employees may face challenges transitioning to a public company.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1818382&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.